On Air Now

Current Show

The Rush Limbaugh Show   11:00 AM - 2:00 PM

Call The Rush Limbaugh Show at 1-800-282-2882.

Show Info »

Upcoming Shows

Program Schedule »


Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI


Current Conditions(Wausau,WI 54403)

More Weather »
73° Feels Like: 73°
Wind: WSW 9 mph Past 24 hrs - Precip: 0”
Current Radar for Zip


Mostly Sunny 74°


Clear 53°


Mostly Sunny 79°


Breaking News

URGENT: Video shows beheading of second American journalist

DUBAI (Reuters) - The Islamic State militant group released a video purporting to show the beheading of U.S. hostage Steven Sotloff, the SITE monitoring service reported on Tuesday. A masked figure in the video also issued a threat against a British hostage, a man the group named as David Haines, and warned governments to back off "this evil alliance of America against the Islamic State", the monitoring service said. (Reporting by William Maclean, Editing by Angus MacSwan)

Read More »

Biogen's blood disorder drug succeeds in late-stage trial

(Reuters) - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.

The drug, Eloctate, was able to maintain low bleeding rates in children with hemophilia A - a rare genetic disorder in which a person's blood does not clot properly due to missing or reduced levels of a protein called factor VIII.

The late-stage trial tested Eloctate in previously treated children under 12 years with severe hemophilia A.

The main goal of the study was to evaluate the frequency of antibody development that can interfere with the therapy and none were detected.

Eloctate is a long-acting hemophilia treatment that was given to patients as twice-weekly preventive injections.

Hemophilia drugs generally need to be infused every two or three days to prevent bleeding episodes.

Biogen and Swedish Orphan Biovitrum have also developed another hemophilia drug, Alprolix, that was approved by the U.S. Food and Drug Administration last month for treating hemophilia B. Hemophilia B is caused by the absence of the factor IX protein.

Biogen shares were up slightly at $300.92 in premarket trading. They closed at $300.68 on Wednesday on the Nasdaq.

(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)